Company intelligence / Profile preview

Synchrogenix

Wilmington, Delaware, United States

Ownership: Private
Employees: ~50
Development stage: Other

Overview

Synchrogenix was a leading independent regulatory writing Contract Research Organization (CRO), acquired by Certara. The company specialized in providing strategic medical and regulatory writing services to pharmaceutical, biotechnology, and medical device companies globally. It was notable for developing an AI-enabled redaction platform to ensure clinical data transparency and its 'Synchrogenix Writer' software for streamlining regulatory document creation.

Industry: Contract Research Organization

Partnerships

Center for Information and Study of Clinical Research Participation (CISCRP)

Beyond the preview

Go deeper on Synchrogenix.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Synchrogenix.

Explore the full profile